FINWIRES · TerminalLIVE
FINWIRES

Johnson & Johnson Says Lung Cancer Study on Rybrevant Plus Lazcluze Suggests Potential for More Durable Disease Control

By

Johnson & Johnson (JNJ) said Friday that updated Phase 1/1b CHRYSALIS-2 data showed Rybrevant plus Lazcluze achieved a median overall survival of 41 months in patients with advanced non-small cell lung cancer with atypical epidermal growth factor receptor mutations.

The company said the results add to the evidence showing potential of this combination to deliver durable survival outcomes in both common and atypical EGFR-mutated advanced NSCLC in the first-line setting.

The company said the combination previously demonstrated a 57% objective response rate and showed consistent clinical activity across atypical EGFR mutation subgroups.

Price: $224.71, Change: $-6.09, Percent Change: -2.64%

Related Articles

Wire

Regency Centers Shares Fall After Deutsche Bank Downgrade

Regency Centers (REG) shares were down about 1.5% in Friday trading after Deutsche Bank downgraded the stock to hold from buy while raising its price target to $85 from $83.Trading volume stood at more than 678,000 shares, compared with a daily average of about 1.4 million.Price: $77.28, Change: $-1.24, Percent Change: -1.58%

$REG
Wire

Cogent Communications Shares Fall After JPMorgan Downgrade

Cogent Communications (CCOI) shares fell 11.5% in Friday afternoon trading after JPMorgan downgraded the stock to neutral from overweight, with a price target of $22 per share.Trading volume stood at over 1.1 million shares, against a daily average of about 1.2 million.Price: $17.53, Change: $-2.29, Percent Change: -11.55%

$CCOI
Wire

AGNC Investment Launches $2 Billion At-The-Market Offering

AGNC Investment (AGNC) announced Friday an at-the-market offering program to sell up to $2 billion of its common stock from time to time.Shares fell around 1.2% in recent trading.Price: $10.43, Change: $-0.12, Percent Change: -1.14%

$AGNC